Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cance...
Pfizer Inc. (NYSE: PFE) will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematolo...
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) announced that it will proceed with a 1-for-20 reverse stock sp...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Eli Lilly and Company (NYSE: LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® ...
Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering fr...
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced that it has receive...
The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet med...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, announced ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced The New England Journal of Medicine ( NEJM ) published the full results from the co...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
© 2024 Biopharma Boardroom. All Rights Reserved.
